This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Ecolab (ECL) to Aid Life Sciences Industry With New Offering
by Zacks Equity Research
Ecolab (ECL) unveils new virtual service offering to help the life sciences industry to address cleaning and disinfection challenges.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.
DaVita's (DVA) Deal to Aid Patients in Kidney Transplantation
by Zacks Equity Research
DaVita (DVA) and NKF collaborate to help kidney patients seeking a living donor, thereby improving health equity in kidney transplant process.
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
5 Probable MedTech Winners Post-COVID on Discounted PEG
by Zacks Equity Research
Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.
Cardinal Health's (CAH) Arm Receives FDA Nod for LYMPHOSEEK
by Zacks Equity Research
Cardinal Health's (CAH) Nuclear & Precision Health Solutions receive FDA approval for LYMPHOSEEK injection.
BD's (BDX) Milestone Pandemic Orders to Support Vaccinations
by Zacks Equity Research
BD (BDX) receives 2 billion pandemic orders for needles and syringes to support global COVID-19 vaccination efforts.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.
AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System
by Zacks Equity Research
AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.
DENTSPLY SIRONA (XRAY) Boosts Clear Aligner Foothold With Buyout
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) to fortifies its presence further in the clear aligner market with the acquisition of Propel Orthodontics.
BD (BDX) Solidifies Foothold in Healthcare Cybersecurity
by Zacks Equity Research
BD's (BDX) authorization as a CNA is expected to allow it to provide customers with timely information about vulnerabilities in BD products available globally.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Baxter (BAX) Unveils New Digital Health Module for PD Patients
by Zacks Equity Research
Baxter (BAX) introduces new clinical management resource within the Sharesource remote patient management platform for home dialysis patients.
DVA vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. AMED: Which Stock Is the Better Value Option?
LHC Group (LHCG) Expands Hospice Presence with New Buyout
by Zacks Equity Research
LHC Group (LHCG) agrees to purchase Heart of Hospice to extend its hospice footprint in five states.
Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio
by Zacks Equity Research
Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Here's Why You Should Retain PRA Health (PRAH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.
Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies
by Zacks Equity Research
Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.
Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark
by Zacks Equity Research
Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
by Zacks Equity Research
BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.
NextGen (NXGN) Announces Positive Telehealth Survey Results
by Zacks Equity Research
NextGen's (NXGN) recent survey indicates growing preference for telehealth services.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.
Allscripts (MDRX), Lash Group Team Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration to streamline specialty medication management for medical clinics and practices across the nation.